MX2009006893A - Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales. - Google Patents

Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales.

Info

Publication number
MX2009006893A
MX2009006893A MX2009006893A MX2009006893A MX2009006893A MX 2009006893 A MX2009006893 A MX 2009006893A MX 2009006893 A MX2009006893 A MX 2009006893A MX 2009006893 A MX2009006893 A MX 2009006893A MX 2009006893 A MX2009006893 A MX 2009006893A
Authority
MX
Mexico
Prior art keywords
cattle
animals
pharmaceutical compositions
treating inflammation
disclosed
Prior art date
Application number
MX2009006893A
Other languages
English (en)
Inventor
Allan J Weingarten
Robert D Simmons
Keith Alan Freehauf
Cheyney Meadows
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of MX2009006893A publication Critical patent/MX2009006893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan nuevas preparaciones transdérmicas que combinan un fármaco anti-inflamatorio no esteroide (NSAID) tales como flunixina; también se divulgan métodos para utilizar y administrar dicha preparación en el tratamiento de afecciones inflamatorias en bovinos, que incluyen la enfermedad respiratoria bovina.
MX2009006893A 2006-12-20 2007-12-18 Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales. MX2009006893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87090706P 2006-12-20 2006-12-20
PCT/US2007/025808 WO2008082507A2 (en) 2006-12-20 2007-12-18 Pharmaceutical compositions and method for treating inflammation in cattle and other animals

Publications (1)

Publication Number Publication Date
MX2009006893A true MX2009006893A (es) 2009-07-03

Family

ID=39262615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006893A MX2009006893A (es) 2006-12-20 2007-12-18 Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales.

Country Status (19)

Country Link
US (1) US9006272B2 (es)
EP (1) EP2120860B1 (es)
JP (1) JP5377326B2 (es)
KR (1) KR20090091328A (es)
CN (2) CN101588789B (es)
AR (1) AR064425A1 (es)
AU (1) AU2007339312B2 (es)
BR (1) BRPI0720500B1 (es)
CA (1) CA2672964C (es)
CL (1) CL2007003711A1 (es)
CO (1) CO6190598A2 (es)
ES (1) ES2714550T3 (es)
MX (1) MX2009006893A (es)
NZ (1) NZ598554A (es)
PE (1) PE20081406A1 (es)
RU (1) RU2466715C2 (es)
TW (1) TWI350182B (es)
WO (1) WO2008082507A2 (es)
ZA (1) ZA200904329B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010050889A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
CA2828086C (en) 2010-03-10 2018-07-31 Nuvo Research Inc. Foamable formulation
WO2012022837A1 (en) * 2010-08-16 2012-02-23 Helsingin Yliopisto Transdermal compositions
WO2012043701A1 (ja) * 2010-09-30 2012-04-05 富山化学工業株式会社 経皮吸収製剤
US20160008471A1 (en) * 2013-02-27 2016-01-14 Laurie Robert Batt Transdermal formulations
CN105769827B (zh) * 2016-03-09 2018-07-17 金陵科技学院 用于动物清热镇痛氟尼辛葡甲胺涂膜剂及其制备方法
KR20200065711A (ko) 2018-11-30 2020-06-09 한원경 동물 피부질환 개선용 조성물
WO2021010843A1 (en) 2019-07-16 2021-01-21 Donaghys Limited Transdermal solvent system and methods of use
US11419876B2 (en) 2019-09-06 2022-08-23 Iowa State University Research Foundation, Inc. Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease
CN116457021A (zh) * 2020-11-25 2023-07-18 英特维特国际股份有限公司 通过氟尼辛的颊部施用治疗疼痛的方法
WO2022238965A1 (en) * 2021-05-12 2022-11-17 Argenta Innovation Limited Veterinary transdermal formulation
CN114404360B (zh) * 2021-12-16 2023-03-28 江西益昕葆生物科技有限公司 一种氟尼辛葡甲胺注射液的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225316A (ja) * 1986-10-21 1988-09-20 Nitto Electric Ind Co Ltd 外皮投与用組成物
JPH11222443A (ja) * 1997-11-11 1999-08-17 Saitama Daiichi Seiyaku Kk 経皮吸収促進組成物および経皮吸収製剤
AU1780101A (en) * 1999-11-19 2001-05-30 Xel Herbaceuticals Transdermal delivery system for alkaloids of aconitum species
JP4865958B2 (ja) * 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
WO2005009510A2 (en) 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
EP1651210A1 (en) * 2003-07-31 2006-05-03 Pharmacia & Upjohn Company LLC Dispersible formulation of an anti-inflammatory agent
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
RU2006147288A (ru) * 2004-07-19 2008-08-27 Уорнер-Ламберт Компани Эл-Эл-Си (US) Препарат для стимуляции роста волос
CA2580286A1 (en) * 2004-09-16 2006-03-23 Bayer Healthcare Ag Dermally applicable formulations for treating skin diseases in animals
US20070116730A1 (en) * 2005-11-21 2007-05-24 Schering-Plough Animal Health Corp. Pharmaceutical compositions

Also Published As

Publication number Publication date
BRPI0720500A2 (pt) 2014-02-04
CN101588789B (zh) 2013-12-11
BRPI0720500B1 (pt) 2019-01-02
US9006272B2 (en) 2015-04-14
CN101588789A (zh) 2009-11-25
NZ598554A (en) 2013-08-30
EP2120860B1 (en) 2019-01-23
RU2466715C2 (ru) 2012-11-20
BRPI0720500A8 (pt) 2015-12-29
AU2007339312A1 (en) 2008-07-10
CO6190598A2 (es) 2010-08-19
CN103690471A (zh) 2014-04-02
AR064425A1 (es) 2009-04-01
CN103690471B (zh) 2015-11-18
TW200833367A (en) 2008-08-16
CL2007003711A1 (es) 2008-07-25
CA2672964C (en) 2018-04-03
RU2009127500A (ru) 2011-01-27
PE20081406A1 (es) 2008-10-17
CA2672964A1 (en) 2008-07-10
KR20090091328A (ko) 2009-08-27
ES2714550T3 (es) 2019-05-29
JP5377326B2 (ja) 2013-12-25
WO2008082507A2 (en) 2008-07-10
JP2010513500A (ja) 2010-04-30
US20080153885A1 (en) 2008-06-26
AU2007339312B2 (en) 2013-06-06
WO2008082507A3 (en) 2009-03-19
EP2120860A2 (en) 2009-11-25
ZA200904329B (en) 2010-05-26
TWI350182B (en) 2011-10-11

Similar Documents

Publication Publication Date Title
TW200833367A (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
MY135791A (en) Compositions and method for treating infection in cattle and swine
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
MX2009013574A (es) Formas de dosificacion solidas o semisolidas de liberacion modificada.
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
MX2009005339A (es) Suspensiones analgesicas de liberacion modificada.
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
HK1127288A1 (en) Pharmaceutical combination comprising 3- (3-dimethylamino-1-ethyl-2-methyl- propyl) -phenol and an nsaid
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
BRPI0810336A2 (pt) "método para tratar e/ou prevenir úlceras de pele em um indivíduo"
DK2012764T3 (da) Farmaceutisk kombination omfattende 3-(3-dimethylamino-1-ethyl-2methyl-propyl)-phenol og paracetamol
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
IN2009CN03512A (es)
JP2017531042A (ja) ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用
TW200600094A (en) Pharmaceutical compositions for prevention or treatment of disorders of lipid metabolism
WO2007067753A3 (en) Methods of reducing side effects in cancer therapy
WO2006081088A3 (en) Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an nsaid
EA200701086A1 (ru) Производные изоксазола, их фармацевтические композиции и способ лечения невропатической боли

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights

Owner name: INTERVET INTERNATIONAL B.V.

FG Grant or registration